神经内镜辅助引流与钻孔引流治疗慢性硬膜下血肿(URANUS):多中心随机对照试验方案
本研究为前瞻性多中心开放标签随机对照试验,计划纳入770例18-90岁影像学确诊的症状性慢性硬膜下血肿患者,比较神经内镜辅助引流与钻孔引流。主要终点为术后3个月内需再干预的复发性血肿,旨在验证神经内镜辅助引流降低复发率及改善临床结局的疗效与安全性。
要点
- 标准钻孔引流术后复发率为5-33%,残余血肿体积是复发的独立预测因素。
- 本试验主要终点为术后3个月内需再干预的复发性血肿。
核心结论
- 本研究旨在验证神经内镜辅助引流相比钻孔引流能否降低慢性硬膜下血肿的复发率并改善临床结局。
研究设计与样本
- 前瞻性、多中心、开放标签、随机对照试验,采用盲法终点评估。
- 计划纳入770例年龄18-90岁、影像学确诊的症状性慢性硬膜下血肿患者。
- 患者随机分配至神经内镜辅助引流组(干预组)或钻孔开颅引流组(对照组)。
主要发现
- 标准钻孔开颅冲洗及硬膜下闭式引流植入的复发率为5-33%,残余血肿体积是复发的独立预测因素。
- Meta分析提示内镜引导引流可能通过优化血肿清除降低复发,但缺乏稳健的临床验证。
关键数值与推荐
- 主要终点:术后3个月内需再干预的复发性血肿发生。
- 次要终点包括术后血肿体积、厚度、中线移位、神经功能评分、生活质量、引流管留置时间、总住院时长、全因死亡率及操作相关并发症发生率。
临床怎么用
- 若验证有效,神经内镜辅助引流可能成为降低慢性硬膜下血肿术后复发的手术选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic subdural hematoma (CSDH), a highly prevalent neurosurgical condition predominantly affecting the elderly, demonstrates an incidence of 58.1/100,000 person-years in individuals ≥ 65 years, escalating to 127/100,000 among octogenarians. Driven by global demographic aging and anticoagulant utilization, its population-level incidence is projected to reach 17.4/100,000 by 2030. The standard surgical intervention-burr hole craniotomy with intraoperative irrigation and closed subdural drainage implantation-carries a documented recurrence rate of 5-33%, where residual hematoma volume constitutes a well-established independent recurrence predictor. Meta-analysis indicates endoscopically guided drainage may reduce recurrence through optimized hematoma evacuation, though robust clinical validation of its therapeutic benefit remains insufficient. METHODS: This prospective, multicenter, open-label, randomized controlled trial employing blinded endpoint assessment will enroll 770 participants aged 18-90 years with radiologically verified symptomatic CSDH. Eligible patients will be randomized to receive neuroendoscopy-assisted drainage (intervention cohort) or burr hole craniotomy drainage (control cohort), with the primary endpoint defined as the occurrence of recurrent hematoma necessitating reintervention within 3 postoperative months. Secondary outcomes comprise postoperative hematoma volume, thickness, and midline shift; neurological function evaluated using standardized assessment scales; quality-of-life measures quantified via validated instruments; catheter indwelling time for subdural drainage; total hospitalization length of stay; all-cause mortality; and incidence of procedure-associated complications. DISCUSSION: This study aims to validate the efficacy and safety of neuroendoscopy-assisted drainage for reducing recurrence rates and improving clinical outcomes in CSDH patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT07144423 . Registered on Aug 27, 2025.
引用
- Wu L, Yan Y, Deng Y, et al. Neuroendoscopy-assisted drainage versus burr hole drainage for chronic subdural hematoma (URANUS): study protocol for a multicenter randomized controlled trial. Trials. 2026. PMID: 41845395. doi:10.1186/s13063-026-09629-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。